Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347968 | 0.84 | PTGS1 (0.59) | CES2SRD5A2PTGS1MAPTMEN1 | |
| SCHEMBL5483962 | 0.80 | MAPT (0.53) | CES2SRD5A2MAPTMEN1ALDH1A1 | |
| SCHEMBL30318 | 0.80 | MPO (0.51) | CES2SRD5A2PTGS1MAPTMEN1 | |
| SCHEMBL1877051 | 0.78 | MAPT (0.64) | MAPTMEN1ALDH1A1ADORA1KMT2A | |
| SCHEMBL29980197 | 0.78 | MAPT (0.64) | MAPTMEN1ALDH1A1ADORA1KMT2A | |
| SCHEMBL6854416 | 0.78 | ALOX15 (0.51) | MAPTALDH1A1KMT2A | |
| SCHEMBL1237189 | 0.78 | SRD5A2 (0.79) | CES2SRD5A2MAPTMEN1ALDH1A1 | |
| SCHEMBL3486347 | 0.77 | MAPT (0.61) | CES2SRD5A2PTGS1MAPTALDH1A1 | |
| SCHEMBL4710822 | 0.75 | MEN1 (0.54) | CES2SRD5A2PTGS1MAPTMEN1 | |
| SCHEMBL2079912 | 0.75 | VNN1 (0.51) | CES2SRD5A2PTGS1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | CES2 192/4885SRD5A2 1212/4885PTGS1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.